advanced search
Frédérique Bordes-Picard
Vice-President, Business Development, Europe
Nanoform

Is this your profile?

About

Frederique Bordes-Picard is Vice-President, Business Development, Europe at Nanoform. A biochemist engineer by training (Bordeaux Polytechnic Institute, France), she also holds an MBA from KEDGE Business School (Bordeaux, France).

Ms Bordes-Picard  has nearly 25 years’ experience in the pharmaceutical industry, gained first at AstraZeneca, UK working on the analytical development of therapeutic proteins and antibodies. She subsequently worked within the CDMO Bertin Pharma (now Eurofins), focusing mainly on generic product development and licensing. Frederique then spent then over 10 years at Capsugel, now Lonza, as Pharmaceutical Business Development Manager, providing technical and regulatory guidance in encapsulation solutions for new drug products for oral or pulmonary administration.

Contributions

EXPERT VIEW
NANOTECHNOLOGY: A NEXT-GENERATION TOOL FOR PULMONARY & NASAL DELIVERY
Frédérique Bordes-Picard looks at the role of nanotechnology in the nasal and pulmonary routes of drug delivery and explains how nanoparticle explains how nanoparticle solutions could transform patient comfort and compliance.

More contributions

ROUNDTABLE
ROUNDTABLE: CAPSULE-BASED DRY POWDER INHALERS
Frédérique Bordes-Picard of Lonza, Marco Franza of Berry, Mirjam Kobler of Meggle, and Marco Laackmann of Harro Höfliger, discuss the accelerating development potential of capsule-based dry powder inhalers (DPIs) and the potential of these effective and efficient drug delivery devices in the modern drug delivery market.
GI/ORAL
REMOVING CLINICAL TRIAL BIAS WITH OVER-ENCAPSULATION
Frédérique Bordes-Picard, Julien Lamps and Stephen Rode discuss the considerations to take into account when using over-encapsulation to blind clinical trials, including the advantages of hydroxypropyl methylcellulose over gelatin as a material.
PULMONARY
AN ADVANCED CUSTOMISABLE COMPREHENSIVE DPI CAPSULE PORTFOLIO OFFERING
Frédérique Bordes-Picard and Julien Lamps discuss the factors driving development in the area of capsule-based dry powder inhalers, and how the company’s Capsugel® Zephyr™ portfolio offering is perfectly positioned to meet and exceed industry’s growing and evolving requirements.
EXPERT VIEW
ADVANCED CAPSULE TECHNOLOGIES: DRY POWDER INHALERS TO TARGET DISEASE
Frédérique Bordes-Picard  and Julien Lamps discuss the value of capsule-based dry powder inhalers in the modern respiratory market, the factors driving development in this area and considerations for matching a capsule to a device and formulation.
Top